Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1

NCT03694522 is registered in ClinicalTrials.gov with Five Prime Therapeutics, Inc. as lead sponsor.

NCT NCT03694522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03694522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1
Lead sponsor
Five Prime Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
September 14, 2018
Completion date
May 13, 2022
Enrollment
155 (actual)
Sites
189

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer